No significant difference was seen on cancer-specific survival in CRC in relation to the NOS2/CD163 ratio, neither in all CRC cases (Figure 4A) nor in the selected group of potentially curatively resected colon cancers (Figure 4B). This evidence concerns the gene CD163 and cancer.